English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Assesing curability of Ombitasvir/Paritaprevir/Ritonavir regimen in chronic HCV infected patients in those with ESRD and CKD. Aim of Work: To asses, curability of Ombitasvir/Paritaprevir/Ritonavir in chronic HCV infected patients in those with ESRD vs CKD, and assess duration of sustained viral therapy in Assiut Hospital University. Patients and Methods: It is a prospective study which included 40 patients at Hemodialysis unit and Internal Medicine department in Assiut University Hospitals though one year. Then Patient will be divided into 2 group: Group I: 20 ESRD Patients on regular heamodialysis >6 months with chronic HCV infection. Group II: 20 CKD Patients with chronic HCV infection did not start dialysis. Results: (SVR) was assessed at 12 and 24 weeks posttherapy. All patients in each group achieved SVR at 12 weeks but at 24 week. 85% of patients with ESRD achieved SVR while all those with CKD achieved SVR. Conclusion: We found that the curability of Ombitasvir /Paritaprevir/Ritonavir plus Ribavirin has SVR12 about 100% and SVR24 100% in CKD patients, 85% in ESRD patients. With less incidence of anemia with that regimen as only 10% patients need blood transfusion. With high tolerability and less side effects with no occurrence of discontinuation of treatment.

the medical journal of cairo university/the medical journal of cairo university

Evaluation of the Clinical Effects of Ombitasvir/Paritaprevir/ Ritonavir Regimen in the Treatment of Chronic HCV Patients in CKD Versus ESRD Patients in Assiut University Hospital